KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Financing Activities (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Cash from Financing Activities for 6 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 0.65% year-over-year to $4.1 million, compared with a TTM value of $14.1 million through Dec 2025, up 10.28%, and an annual FY2025 reading of $14.1 million, up 10.28% over the prior year.
  • Cash from Financing Activities was $4.1 million for Q4 2025 at AbCellera Biologics, down from $7.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $7.4 million in Q3 2025 and bottomed at -$5.1 million in Q2 2021.
  • Average Cash from Financing Activities over 5 years is $1.6 million, with a median of $1.5 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities plummeted 1566.76% in 2021, then soared 34994.74% in 2023.
  • Year by year, Cash from Financing Activities stood at $1.8 million in 2021, then crashed by 80.97% to $349000.0 in 2022, then skyrocketed by 978.8% to $3.8 million in 2023, then rose by 10.01% to $4.1 million in 2024, then fell by 0.65% to $4.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ABCL at $4.1 million in Q4 2025, $7.4 million in Q3 2025, and -$3.4 million in Q2 2025.